EGFR and neoplasm: The ADC, but not cetuximab alone, could induce cell cycle arrest and engender cytotoxic functions specifically against EGFR-high tumor cells, with subsequent release of free payloads to trigger bystander cytotoxicity against neighboring EGFR-low cells in the heterogenic tumor microenvironments.